journal
MENU ▼
Read by QxMD icon Read
search

Movement Disorders: Official Journal of the Movement Disorder Society

journal
https://read.qxmd.com/read/31412430/focused-ultrasound-in-parkinson-s-disease-a-twofold-path-toward-disease-modification
#1
REVIEW
Guglielmo Foffani, Inés Trigo-Damas, José A Pineda-Pardo, Javier Blesa, Rafael Rodríguez-Rojas, Raul Martínez-Fernández, José A Obeso
A major unmet need in Parkinson's disease (PD) is to slow the inexorable progression of neurodegeneration. Clinical trials that evaluated promising pharmacological strategies have repeatedly failed. Nonetheless, the advent of focused ultrasound provides new opportunities toward the goal of developing a safe and effective disease-modifying therapy for PD. Here we discuss the rationale, possible avenues, and challenges along this path, exploiting the potential of focused ultrasound for (1) performing focal thermal lesions to restore the basic basal ganglia abnormalities associated with dopamine depletion, and (2) transiently opening the blood-brain barrier for targeted delivery of therapeutic agents...
August 14, 2019: Movement Disorders: Official Journal of the Movement Disorder Society
https://read.qxmd.com/read/31412427/update-of-the-mds-research-criteria-for-prodromal-parkinson-s-disease
#2
REVIEW
Sebastian Heinzel, Daniela Berg, Thomas Gasser, Honglei Chen, Chun Yao, Ronald B Postuma
The MDS Research Criteria for Prodromal PD allow the diagnosis of prodromal Parkinson's disease using an evidence-based conceptual framework, which was designed to be updated as new evidence becomes available. New prospective evidence of predictive values of risk and prodromal markers published since 2015 was reviewed and integrated into the criteria. Many of the predictive values (likelihood ratios, LR) remain unchanged. The positive likelihood ratio notably increase for olfactory loss and decreased for substantia nigra hyperechogenicity...
August 14, 2019: Movement Disorders: Official Journal of the Movement Disorder Society
https://read.qxmd.com/read/31361367/longitudinal-analyses-of-cerebrospinal-fluid-%C3%AE-synuclein-in-prodromal-and-early-parkinson-s-disease
#3
Brit Mollenhauer, Chelsea J Caspell-Garcia, Christopher S Coffey, Peggy Taylor, Andy Singleton, Leslie M Shaw, John Q Trojanowski, Mark Frasier, Tanya Simuni, Alex Iranzo, Wolfgang Oertel, Andrew Siderowf, Daniel Weintraub, John Seibyl, Arthur W Toga, Caroline M Tanner, Karl Kieburtz, Lana M Chahine, Kenneth Marek, Douglas Galasko
BACKGROUND: Aggregation of α-synuclein is central to the pathophysiology of PD. Biomarkers related to α-synuclein may be informative for PD diagnosis/progression. OBJECTIVES: To analyze α-synuclein in CSF in drug-naïve PD, healthy controls, and prodromal PD in the Parkinson's Progression Markers Initiative. METHODS: Over up to 36-month follow-up, CSF total α-synuclein and its association with MDS-UPDRS motor scores, cognitive assessments, and dopamine transporter imaging were assessed...
July 30, 2019: Movement Disorders: Official Journal of the Movement Disorder Society
https://read.qxmd.com/read/31361359/revising-rapid-onset-dystonia-parkinsonism-broadening-indications-for-atp1a3-testing
#4
Ihtsham U Haq, Beverly M Snively, Kathleen J Sweadner, Cynthia K Suerken, Jared F Cook, Laurie J Ozelius, Charlotte Miller, William V McCall, Christopher Whitlow, Allison Brashear
BACKGROUND AND OBJECTIVES: Rapid-onset dystonia-parkinsonism (RDP) is caused by mutations in the ATP1A3 gene, which codes for the α-3 subunit of the Na+ /K+ ATPase. It has been characterized by rapid-onset bulbar dysfunction, limb dystonia, bradykinesia, and a rostrocaudal spatial gradient of expression, usually after a physiologic trigger. We reexamined whether these features were in fact characteristic. METHODS: We characterized phenotypic variation within a cohort of 50 ATP1A3 mutation-positive individuals (carriers) and 44 mutation-negative family members (noncarriers)...
July 30, 2019: Movement Disorders: Official Journal of the Movement Disorder Society
https://read.qxmd.com/read/31361357/insensitivity-to-loss-predicts-apathy-in-huntington-s-disease
#5
Duncan J McLauchlan, Thomas Lancaster, David Craufurd, David E J Linden, Anne E Rosser
BACKGROUND: Apathy is a deficit in goal-directed behavior that significantly affects quality of life and function. It is common in Huntington's disease and other disorders affecting corticostriatal pathways. Deficits in processing of reward, altered effort, and executive dysfunction are associated with apathy in other disorders, but the cognitive processes leading to apathy in Huntington's disease remain largely unknown. A previously reported deficit in learning from losses in Huntington's disease raises the possibility of a hitherto unrecognized mechanism leading to apathy...
July 30, 2019: Movement Disorders: Official Journal of the Movement Disorder Society
https://read.qxmd.com/read/31361356/blood-brain-barrier-opening-with-focused-ultrasound-in-experimental-models-of-parkinson-s-disease
#6
REVIEW
Maria Eleni Karakatsani, Javier Blesa, Elisa Evgenia Konofagou
Parkinson's disease has many symptomatic treatments, but there is no neuroprotective therapy currently available. The evolution of this disease is inexorably progressive, and halting or stopping the neurodegenerative process is a major unmet need. Parkinson's disease motor features at onset are typically limited to 1 body segment, that is, focal signs, and the nigrostriatal degeneration is highly asymmetrical and mainly present in the caudal putamen. Thus, clinically and neurobiologically the process is fairly limited early in its evolution...
July 30, 2019: Movement Disorders: Official Journal of the Movement Disorder Society
https://read.qxmd.com/read/31348550/distinct-subthalamic-coupling-in-the-on-state-describes-motor-performance-in-parkinson-s-disease
#7
Musa Ozturk, Aviva Abosch, David Francis, Jianping Wu, Joohi Jimenez-Shahed, Nuri F Ince
OBJECTIVE: Cross-frequency coupling has been reported in the STN of patients with PD, but its significance and functional role are still not well understood. This study investigates pharmacological modulations of subthalamic oscillations and their nonlinear cross-frequency interactions across three consecutive cycles over unique 24-hour-long recordings. BACKGROUND: Identifying neurobiomarkers for PD can drive the development of novel personalized treatments by providing objective assessment of impairment...
July 26, 2019: Movement Disorders: Official Journal of the Movement Disorder Society
https://read.qxmd.com/read/31348549/cancer-outcomes-among-parkinson-s-disease-patients-with-leucine-rich-repeat-kinase-2-mutations-idiopathic-parkinson-s-disease-patients-and-nonaffected-controls
#8
Ilir Agalliu, Roberto A Ortega, Marta San Luciano, Anat Mirelman, Claustre Pont-Sunyer, Kathrin Brockmann, Dolores Vilas, Eduardo Tolosa, Daniela Berg, Bjørg Warø, Amanda Glickman, Deborah Raymond, Rivka Inzelberg, Javier Ruiz-Martinez, Elisabet Mondragon, Eitan Friedman, Sharon Hassin-Baer, Roy N Alcalay, Helen Mejia-Santana, Jan Aasly, Tatiana Foroud, Karen Marder, Nir Giladi, Susan Bressman, Rachel Saunders-Pullman
BACKGROUND: Increased cancer risk has been reported in Parkinson's disease (PD) patients carrying the leucine rich repeat kinase 2 (LRRK2) G2019S mutation (LRRK2-PD) in comparison with idiopathic PD (IPD). It is unclear whether the elevated risk would be maintained when compared with unaffected controls. METHODS: Cancer outcomes were compared among 257 LRRK2-PD patients, 712 IPD patients, and 218 controls recruited from 7 LRRK2 consortium centers using mixed-effects logistic regression...
July 26, 2019: Movement Disorders: Official Journal of the Movement Disorder Society
https://read.qxmd.com/read/31335998/immunomodulatory-drugs-alleviate-l-dopa-induced-dyskinesia-in-a-rat-model-of-parkinson-s-disease
#9
Laura Boi, Augusta Pisanu, Nigel Greig, Michael T Scerba, David Tweedie, Giovanna Mulas, Sandro Fenu, Ezio Carboni, Saturnino Spiga, Anna R Carta
BACKGROUND: Thalidomide and closely related analogues are used clinically for their immunomodulatory and antiangiogenic properties mediated by the inhibition of the proinflammatory cytokine tumor necrosis factor α. Neuroinflammation and angiogenesis contribute to classical neuronal mechanisms underpinning the pathophysiology of l-dopa-induced dyskinesia, a motor complication associated with l-dopa therapy in Parkinson's disease. The efficacy of thalidomide and the more potent derivative 3,6'-dithiothalidomide on dyskinesia was tested in the 6-hydroxydopamine Parkinson's disease model...
July 23, 2019: Movement Disorders: Official Journal of the Movement Disorder Society
https://read.qxmd.com/read/31322768/value-of-in-vivo-%C3%AE-synuclein-deposits-in-parkinson-s-disease-a-systematic-review-and-meta-analysis
#10
REVIEW
Kazuto Tsukita, Haruhi Sakamaki-Tsukita, Kanta Tanaka, Toshihiko Suenaga, Ryosuke Takahashi
Previous studies that have investigated the potential of in vivo abnormal α-synuclein deposits as a pathological biomarker for PD included few participants and reported different diagnostic accuracies. Here, we aimed to confirm the diagnostic value of in vivo α-synuclein deposits in PD through a systematic review and meta-analysis, with special emphasis on determining the tissue most suitable for examination and assessing whether anti-native α-synuclein or anti-phosphorylated α-synuclein antibodies should be used...
July 19, 2019: Movement Disorders: Official Journal of the Movement Disorder Society
https://read.qxmd.com/read/31322758/magnetic-resonance-imaging-visible-perivascular-spaces-in-basal-ganglia-predict-cognitive-decline-in-parkinson-s-disease
#11
Yae Won Park, Na-Young Shin, Seok Jong Chung, Jiwoong Kim, Soo Mee Lim, Phil Hyu Lee, Seung-Koo Lee, Kook Jin Ahn
BACKGROUND: Growing evidence suggests an association between imaging biomarkers of small vessel disease and future cognitive decline in Parkinson's disease (PD). Recently, magnetic resonance imaging-visible perivascular space (PVS) has been considered as an imaging biomarker of small vessel disease, but its effect on cognitive decline in PD is yet to be investigated. OBJECTIVE: The objective of this study was to evaluate whether PVS can independently predict cognitive decline in PD...
July 19, 2019: Movement Disorders: Official Journal of the Movement Disorder Society
https://read.qxmd.com/read/31314148/motor-function-and-the-probability-of-prodromal-parkinson-s-disease-in-older-adults
#12
Maria I Maraki, Leonidas Stefanis, Mary Yannakoulia, Mary H Kosmidis, Georgia Xiromerisiou, Efthimios Dardiotis, Georgios M Hadjigeorgiou, Paraskevi Sakka, Nikolaos Scarmeas, Maria Stamelou
BACKGROUND: Identification and characterization of Parkinson's disease (PD) in its prodromal stage is crucial. OBJECTIVE: The objective of this study was to investigate the association between motor function and the probability of prodromal PD in a community-dwelling older population. METHODS: We used data from a population-based cohort of older adults (HELIAD study). Subjective motor function was evaluated with a 12-item motor symptoms questionnaire and objective motor function indirectly with a physical activity questionnaire and two gait speed tests...
July 17, 2019: Movement Disorders: Official Journal of the Movement Disorder Society
https://read.qxmd.com/read/31309609/early-limbic-microstructural-alterations-in-apathy-and-depression-in-de-novo-parkinson-s-disease
#13
Stéphane Prange, Elise Metereau, Audrey Maillet, Eugénie Lhommée, Hélène Klinger, Pierre Pelissier, Danielle Ibarrola, Rolf A Heckemann, Anna Castrioto, Léon Tremblay, Véronique Sgambato, Emmanuel Broussolle, Paul Krack, Stéphane Thobois
BACKGROUND: Whether structural alterations underpin apathy and depression in de novo parkinsonian patients is unknown. The objectives of this study were to investigate whether apathy and depression in de novo parkinsonian patients are related to structural alterations and how structural abnormalities relate to serotonergic or dopaminergic dysfunction. METHODS: We compared the morphological and microstructural architecture in gray matter using voxel-based morphometry and diffusion tensor imaging coupled with white matter tract-based spatial statistics in a multimodal imaging case-control study enrolling 14 apathetic and 13 nonapathetic patients with de novo Parkinson's disease and 15 age-matched healthy controls, paired with PET imaging of the presynaptic dopaminergic and serotonergic systems...
July 15, 2019: Movement Disorders: Official Journal of the Movement Disorder Society
https://read.qxmd.com/read/31307115/hallucinations-somatic-functional-disorders-of-pd-dlb-as-expressions-of-thalamic-dysfunction
#14
REVIEW
Marco Onofrj, Alberto J Espay, Laura Bonanni, Stefano Delli Pizzi, Stefano L Sensi
Hallucinations, delusions, and functional neurological manifestations (conversion and somatic symptom disorders) of Parkinson's disease (PD) and dementia with Lewy bodies increase in frequency with disease progression, predict the onset of cognitive decline, and eventually blend with and are concealed by dementia. These symptoms share the absence of reality constraints and can be considered comparable elements of the PD-dementia with Lewy bodies psychosis. We propose that PD-dementia with Lewy bodies psychotic disorders depend on thalamic dysfunction promoting a theta burst mode and subsequent thalamocortical dysrhythmia with focal cortical coherence to theta electroencephalogram rhythms...
July 15, 2019: Movement Disorders: Official Journal of the Movement Disorder Society
https://read.qxmd.com/read/31307114/misconceptions-about-speech-impairment-in-parkinson-s-disease
#15
Caroline Moreau, Serge Pinto
No abstract text is available yet for this article.
July 15, 2019: Movement Disorders: Official Journal of the Movement Disorder Society
https://read.qxmd.com/read/31299107/the-genetic-and-clinico-pathological-profile-of-early-onset-progressive-supranuclear-palsy
#16
Edwin Jabbari, John Woodside, Manuela M X Tan, Nicola Pavese, Oliver Bandmann, Boyd C P Ghosh, Luke A Massey, Erica Capps, Tom T Warner, Andrew J Lees, Tamas Revesz, Janice L Holton, Nigel M Williams, Donald G Grosset, Huw R Morris
BACKGROUND: Studies on early-onset presentations of progressive supranuclear palsy (PSP) have been limited to those where a rare monogenic cause has been identified. Here, we have defined early-onset PSP (EOPSP) and investigated its genetic and clinico-pathological profile in comparison with late-onset PSP (LOPSP) and Parkinson's disease (PD). METHODS: We included subjects from the Queen Square Brain Bank, PROSPECT-UK study, and Tracking Parkinson's study. Group comparisons of data were made using Welch's t-test and Kruskal-Wallis analysis of variance...
July 12, 2019: Movement Disorders: Official Journal of the Movement Disorder Society
https://read.qxmd.com/read/31291491/the-role-of-high-intensity-focused-ultrasound-as-a-symptomatic-treatment-for-parkinson-s-disease
#17
REVIEW
Shayan Moosa, Raul Martínez-Fernández, W Jeffrey Elias, Marta Del Alamo, Howard M Eisenberg, Paul S Fishman
MR-guided focused ultrasound is a novel, minimally invasive surgical procedure for symptomatic treatment of PD. With this technology, the ventral intermediate nucleus, STN, and internal globus pallidus have been targeted for therapeutic cerebral ablation, while also minimizing the risk of hemorrhage and infection from more invasive neurosurgical procedures. In a double-blinded, prospective, sham-controlled randomized controlled trial of MR-guided focused ultrasound thalamotomy for treatment of tremor-dominant PD, 62% of treated patients demonstrated improvement in tremor scores from baseline to 3 months postoperatively, as compared to 22% in the sham group...
July 10, 2019: Movement Disorders: Official Journal of the Movement Disorder Society
https://read.qxmd.com/read/31291488/measuring-parkinson-s-disease-over-time-the-real-world-within-subject-reliability-of-the-mds-updrs
#18
Luc J W Evers, Jesse H Krijthe, Marjan J Meinders, Bastiaan R Bloem, Tom M Heskes
BACKGROUND: An important challenge in Parkinson's disease research is how to measure disease progression, ideally at the individual patient level. The MDS-UPDRS, a clinical assessment of motor and nonmotor impairments, is widely used in longitudinal studies. However, its ability to assess within-subject changes is not well known. The objective of this study was to estimate the reliability of the MDS-UPDRS when used to measure within-subject changes in disease progression under real-world conditions...
July 10, 2019: Movement Disorders: Official Journal of the Movement Disorder Society
https://read.qxmd.com/read/31291485/the-locus-coeruleus-another-vulnerability-target-in-parkinson-s-disease
#19
Wolfgang H Oertel, Martin T Henrich, Annette Janzen, Fanni F Geibl
No abstract text is available yet for this article.
July 10, 2019: Movement Disorders: Official Journal of the Movement Disorder Society
https://read.qxmd.com/read/31283857/antisense-therapies-for-movement-disorders
#20
REVIEW
Daniel R Scoles, Stefan M Pulst
Currently, few disease-modifying therapies exist for degenerative movement disorders. Antisense oligonucleotides are small DNA oligonucleotides, usually encompassing ∼20 base pairs, that can potentially target any messenger RNA of interest. Antisense oligonucleotides often contain modifications to the phosphate backbone, the sugar moiety, and the nucleotide base. The development of antisense oligonucleotide therapies spinal muscular atrophy and Duchenne muscular dystrophy suggest potentially wide-ranging therapeutic applications for antisense oligonucleotides in neurology...
July 8, 2019: Movement Disorders: Official Journal of the Movement Disorder Society
journal
journal
29365
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"